Booth Bruce sold $56.5M of KYMR (indirect holdings)
Booth Bruce sold 513,245 indirectly-held shares of Kymera Therapeutics, Inc. (KYMR) at an average of $110.01 ($105.78–$118.66, $56.46M total) across 30 trades over 2026-06-26 to 2026-06-29 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides a concrete datapoint on insider selling size and timing, but it does not include new operational/clinical/regulatory information about Kymera Therapeutics.
Market read
A $56.46M director sale under 10b5-1 is a sentiment datapoint, but it is unlikely to be a standalone fundamental catalyst.
What to watch
Traders may over-weight insider selling; the key incremental signal is whether there are additional filings (other insiders, new grants, or company-specific catalysts) around the same period.
Background
SEC Form 4 reports an insider transaction by Kymera Therapeutics director Booth Bruce, with ownership form listed as indirect and executed under a Rule 10b5-1 plan.
Ticker impact
Kymera Therapeutics director Booth Bruce sold $56.46M of KYMR via an open-market sale under a pre-arranged 10b5-1 plan (513,245 shares).
Likely limited, short-lived sentiment impact; follow-through depends on broader fundamentals and any concurrent company news.
Form 4 discloses a sizable sale ($56.46M) and confirms it was pre-arranged (10b5-1), which typically reduces the signal of new negative information.
Market effects
No direct sector read-across; this is company-specific insider transaction disclosure.
None indicated.
None indicated.
Counterpoint
Because the sale was under a pre-arranged 10b5-1 plan, it may reflect routine liquidity needs rather than a change in outlook.
Key entities
- issuerKymera Therapeutics, Inc.
Subject of the Form 4 insider transaction; director Booth Bruce sold shares under a 10b5-1 plan.
- insiderBooth Bruce
Director who executed the open-market sale of KYMR shares (indirect holdings).
- trading mechanismRule 10b5-1 plan
Pre-arranged plan cited in the filing, typically reducing interpretive weight of the sale.
